Oxidized regenerated cellulose shows comparable hemostasis across liver, gastric, and mesenteric bleeding
Surgeons rely on absorbable topical hemostats when bleeding is diffuse, awkwardly placed, or difficult to control with sutures and cautery alone. In that setting, oxidized regenerated cellulose has long occupied a practical niche: it is placed directly on the bleeding surface, swells into a matrix that helps stabilize clot formation, and then gradually absorbs as tissue healing progresses. The question in this porcine study was not whether the material can work in principle, but whether a domestically produced product could perform with the same functional reliability as an imported comparator across different organ beds.
The comparison was direct and tightly defined. Sixteen male Bama minipigs were assigned to either a liver bleeding model or a gastrointestinal model, with the gastrointestinal arm including both gastric wall and mesentery bleeding sites. Within each model, animals received either StypCel™ or Surgicel® Fibrillar™, and three bleeding sites were created per animal per organ. Investigators then tracked 10-second blood loss, time to hemostasis, intraoperative blood loss, hematology, liver and kidney function, coagulation parameters, and histologic change.
Finer fibers did not translate into measurable clinical advantage
A visible manufacturing difference emerged immediately under the microscope. Both materials formed three-dimensional porous networks, but StypCel™ had significantly finer fibers than Surgicel® Fibrillar™: 9.82 ± 0.93 μm versus 20.59 ± 1.88 μm, with P < 0.001. In theory, a tighter fiber architecture can increase surface area and may influence how blood interacts with the matrix, including capillary action and local clot consolidation. Yet a material that looks different at the microscopic level does not always behave differently at the bedside, especially when the critical outcome is rapid control of bleeding rather than laboratory appearance.
In this experiment, it did not. Across the liver, gastric wall, and mesentery models, no significant differences emerged between groups in time to hemostasis. The time to hemostasis comparisons were non-significant in all three settings, with P values of 0.8759, 0.1578, and 0.9632, respectively. Intraoperative blood loss also failed to separate the materials, with P values of 0.0805 for liver, 0.7673 for gastric wall, and 0.4678 for mesentery bleeding. In practical terms, the domestic product performed like the imported comparator where the surgeon needs it most: at the bleeding surface, in real tissue, under operative conditions.
Organ-specific bleeding did not expose a safety penalty
The study design matters because liver parenchyma, gastric tissue, and mesentery present different hemostatic challenges. Liver bleeding is rich in vascular supply and can be troublesome when surface ooze persists; gastric wall injury adds the mechanical stress of a hollow viscus; mesenteric bleeding often occurs in delicate, mobile tissue where local compression is imperfect. A hemostat that performs well in one compartment can falter in another if it alters the local inflammatory response, degrades too slowly, or interferes with tissue repair.
No such penalty appeared here. Hematologic measurements, liver and kidney function tests, and coagulation parameters remained comparable between groups at all time points, with all P values above 0.05. The absence of divergence in systemic laboratory markers argues against a measurable toxic or procoagulant signal in this animal model. For surgeons and biomaterials specialists, the more relevant point is biological plausibility: oxidized regenerated cellulose is designed to be locally active and absorbable, so a favorable safety profile depends on whether the material stays confined to the wound bed and resolves without driving persistent inflammation or organ dysfunction.
Histology showed parallel degradation and inflammation resolution
Microscopic tissue behavior often determines whether a topical hemostat is truly usable, because the best clotting profile means little if the material provokes ongoing inflammation or delays healing. Histologic analysis showed similar degradation and absorption patterns for both products. Inflammation was essentially resolved by week 4 in each group, which suggests that the wound environment moved through the expected healing sequence rather than remaining locked in a prolonged foreign-body response.
That trajectory is clinically reassuring. Absorbable hemostats are most useful when they disappear after they have served their function, leaving behind stable tissue repair rather than a persistent nidus for irritation. The week 4 resolution window fits that concept and supports the idea that both ORC formulations behaved as temporary scaffolds rather than chronic implants. The material with finer fibers did not produce a more aggressive tissue reaction, and it did not slow apparent absorption.
What this means for topical hemostat selection
This study supports StypCel™ as a functional alternative to Surgicel® Fibrillar™ in a controlled multi-organ bleeding model. The most important message is not that one product outperformed the other, but that the domestic formulation achieved comparable control of bleeding without measurable harm in liver, gastric wall, or mesenteric tissues. In a surgical environment where product availability, cost, and institutional supply chains influence daily choices, equivalence in efficacy and safety can be enough to justify adoption if the operative team is satisfied with handling characteristics and regulatory requirements are met.
Still, the evidence remains preclinical. Minipig tissue is a useful surrogate for human surgery, but it is not a substitute for patient-level outcomes such as delayed hemorrhage, postoperative adhesion formation, infection, reoperation, or real-world effectiveness in contaminated fields. The study also involved a relatively small number of animals, and the injury patterns were standardized rather than emergent. Those constraints limit direct translation to complex human operations, where bleeding is less uniform and hemostatic decisions are shaped by comorbidity, anticoagulant exposure, and surgical technique.
The most actionable conclusion is narrower: a domestically produced oxidized regenerated cellulose with a finer fiber structure produced hemostatic and safety results similar to an imported comparator in three distinct porcine bleeding models. Future human trials will need to determine whether that equivalence holds under operative stress, across specialties, and in the settings where topical hemostats are used most often.